Danske Bank
MDGL icon

Danske Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Danske Bank’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.1K Hold
20
– – ﹤0.01% 798
2026
Q2 		$10.7K Hold
20
– – ﹤0.01% 808
2026
Q1 		$10.5K Sell
20
-180
-90% -$86K ﹤0.01% 799
2025
Q4 		$116K Buy
+200
New +$102K ﹤0.01% 752
2024
Q4 		– Sell
-500
Closed -$106K – 1549
2024
Q3 		$106K Buy
500
+400
+400% +$102K ﹤0.01% 1006
2024
Q2 		$28K Buy
+100
New +$23.8K ﹤0.01% 1032

Other funds holding MDGL

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return

Danske Bank's MDGL Position: Q3 2026 in Review

Danske Bank held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 20 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Danske Bank first reported a position in MDGL in Q2 2024 and has held it in 6 quarters since. The position peaked at $116K in Q4 2025. 244 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Danske Bank held 20 shares of Madrigal Pharmaceuticals worth $10.1K as of Q3 2026.
  • Danske Bank left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #798 holding.
  • Danske Bank first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Danske Bank's Madrigal Pharmaceuticals position peaked at $116K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.